Open AccessIntracranial Response to Anti‐Programmed Death 1 Therapy in a Patient with Metastatic Non‐Small Cell Lung Cancer with Leptomeningeal Carcinomatosis
Author(s) -
Kamath Suneel D.,
Kumthekar Priya U.,
Kruser Tim J.,
Mohindra Nisha A.
Publication year - 2018
Publication title -
the oncologist
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.176
H-Index - 164
eISSN - 1549-490X
pISSN - 1083-7159
DOI - 10.1634/theoncologist.2018-0022
Subject(s) - medicine , radiosurgery , lung cancer , meningeal carcinomatosis , adenocarcinoma , parenchyma , brain metastasis , lung , central nervous system , metastasis , pathology , cancer , oncology , radiology , radiation therapy , cerebrospinal fluid
Central nervous system metastasis in non‐small cell lung cancer remains a therapeutic challenge and confers a poor prognosis. Here we describe a patient with lung adenocarcinoma, parenchymal brain metastases, and leptomeningeal carcinomatosis who demonstrated a sustained response to programmed death 1 inhibition combined with stereotactic radiosurgery.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom